Skip to main content
The American Journal of Case Reports logoLink to The American Journal of Case Reports
. 2022 Mar 3;23:e934396-1–e934396-6. doi: 10.12659/AJCR.934396

A Mixed Neuroendocrine/Non-Neuroendocrine Neoplasm Arising in the Background of Ulcerative Colitis: A Case Report and Review of the Literature

Saud A Al Buthi 1,2,3,B,E,G,, Sultanah F Bin Gheshayan 1,2,3,B,E,F, Ibrahim Al Samaani 1,2,3,B,E,F, Bushra Al Ahmadi 4,E,F, Nahar A Al Selaim 1,2,3,D,E
PMCID: PMC8902805  PMID: 35236818

Abstract

Patient: Female, 57-year-old

Final Diagnosis: Mixed neuroendocrine non-neuroendocrine neoplasm • ulcerative colitis

Symptoms: Abdominal pain • distention • obstruction

Medication: —

Clinical Procedure: Laparoscopic diverting loop colostomy and colonic mass biopsy • open laparotomy and total colectomy with end ileostomy

Specialty: Surgery

Objective:

Rare coexistence of disease or pathology

Background:

Inflammatory bowel disease (IBD) is a chronic, potentially life-long, disorder, including ulcerative colitis (UC) and Crohn’s disease (CD). Ulcerative colitis (UC) is an idiopathic chronic inflammatory disorder affecting the mucosa of the colon; it starts at the rectum and continues proximally in a continuous pattern to include up to the entire colon, called pancolitis. Patients with ulcerative colitis are at particularly higher risk of developing colorectal cancer (CRC) than the general population. Adenocarcinoma is the most common type of colorectal malignancy reported in the general population and IBD patients. One of the rarest types reported are the neuroendocrine neoplasms (NENs), which account for only 1% of all colorectal cancers, and it is very infrequent in IBD patients. Moreover, mixed neuroendocrine/non-neuroendocrine neoplasm (MiNEN) is a rare aggressive subtype of NENs that involves the colon in the background of an underlying chronic inflammatory process.

Case Report:

A 57-year-old woman, known to have long-term cirrhosis and ulcerative colitis, came to the Emergency Department with a suspected large-bowel obstruction. Imaging (CT scan of the abdomen) showed an obstructive transverse colon mass along with multiple descending colon masses. Biopsy of the transverse tumor confirmed the diagnosis of mixed neuroendocrine/non-neuroendocrine neoplasm (MiNEN).

Conclusions:

Although neuroendocrine tumors are rare, strong association exist between MiNENs and ulcerative colitis. Further studies and reports can help better understand the pathogenesis, diagnosis, management, and prognosis of these cases.

Keywords: Abdominal Pain; Colitis, Ulcerative; Colonic Neoplasms; Inflammatory Bowel Diseases; Neuroendocrine Tumors

Background

Ulcerative colitis (UC) a subtype of Inflammatory bowel disease (IBD). Ulcerative colitis (UC) is an idiopathic chronic inflammatory disorder affecting the mucosa of the colon, starts at the rectum and continuing proximally in a continuous pattern to include up to the entire colon, called pancolitis. Patients with ulcerative colitis are particularly more risk of developing colorectal cancer (CRC) than the general population, with an overall risk of 1.29 cases per 1000 IBD patients [1,2]. Among of the rarest types reported are the neuroendocrine neoplasms (NENs), which account for 1% of all colorectal cancers, and it is very infrequent in IBD patients. Moreover, mixed neuroendocrine/non-neuroendocrine neoplasm (MiNEN) is a rare aggressive subtype of NENs that involves the colon in the background of an underlying chronic inflammatory process [3]. With an incidence rate of of 1.16 cases per 1 000 000 individuals [4]. Notably, few case reports have been reported of IBD in relation to MiNEN.

In this report we present such a case, with a thorough literature review.

Case Report

A 57-year-old woman presented to the Emergency Department with a 2-week history of abdominal pain and distension, associated with constipation alternating with loose bowel movements. In addition, the patient reported having constitutional symptoms of weight loss and poor oral intake during the past 2 years.

Twenty years ago, the patient had similar severe abdominal pain associated with diarrhea and rectal bleeding, where the medical team planned to do a colonoscopy due to a suspicion of inflammatory bowel disease. However, the patient refused to follow up, and was not started on any medical therapy. She denied having any similar episodes during this time period.

Upon examining the patient, she looked malnourished and dehydrated, but had normal vital signs. The abdomen was hugely distended, mildly tender, with shifting dullness on percussion.

Laboratory results during admission showed low hemoglobin (9.7 g/dL), sodium 117 mEq/L, and tumor markers only showed high CA-125 (233 U/mL) (normal level <35 U/mL). All other laboratory work-ups were unremarkable and within normal ranges.

Computed tomography (CT) of the abdomen and pelvis was done, which showed a distended large bowel with a cecal diameter of 8.5 cm, down to a short stricture, with one of 2 cm at the mid-transverse colon (Figure 1) and another colonic stricture span for around 5 cm at the distal descending colon (Figure 2). Also, there was a polypoid mass lesion involving the medial colonic wall just distal to descending colon (Figure 3). Signs of inflammation were noted, with irregular mucosal thickening, hyperenhancement, and paracolic fat stranding with lead pipe appearance of the colon suggesting IBD, particularly UC. Moreover, the liver was cirrhotic and showed innumerable hypo-dense micro-nodules with right hepatic vein thrombosis.

Figure 1.

Figure 1.

Computed tomography of the abdomen showing a mid-transverse colon malignant stricture (yellow arrow).

Figure 2.

Figure 2.

Computed tomography of the abdomen showing a splenic flexure colon mass (yellow arrow).

Figure 3.

Figure 3.

Computed tomography of the abdomen showing a distal descending colon mass (yellow arrow).

Further laboratory investigations were done for the patient’s cirrhotic liver, which revealed she had hepatitis C virus (HCV) and was categorized as Child- Pugh score B with ascites and hepatic vein thrombosis.

Given the complexity of the patient’s presentation with the concurrent bowel obstruction and liver cirrhosis, she was not stable and required admission to the Intensive Care Unit (ICU). The plan at that time was to relieve the obstruction temporarily by diverting stoma and performing a biopsy the lesions to appropriately diagnose and stage the patient and optimize her clinical condition for definitive resection and proper planning of the extent of resection.

The pathological examination from the transverse colon mass biopsy demonstrated large cells with adenocarcinoma and neuroendocrine carcinoma morphology. Immunohistochemical staining showed that more than 50% of the tumor was positive for synaptophysin and CDX2, with a Ki67 index of 75%. Moreover, some tumor cells were 40% positive for CK20. Thus, the biopsy was suggestive of poorly-differentiated MiNEN in a background of active chronic colitis, confirming the diagnosis of UC.

Liver magnetic resonance imaging (MRI) was done for further evaluation of the suspicious lesions to exclude metastasis, which showed a redemonstration of the cirrhotic liver, with no concerning focal hepatic lesion.

During her hospital stay and given her co-morbid liver failure and the active colitis, the patient showed no significant improvement despite starting hydrocortisone along with supportive medical management. The case was discussed with the tumor board committee, and the decision was made to proceed with high-risk surgery for total colectomy, given the multiple malignant lesions on the transverse and descending colon in the background of ulcerative colitis. Upon exploring the abdomen, the colon was examined, showing 1 stricture at the transverse colon and another 2 masses at the descending colon. Total colectomy with end-ileostomy were then performed.

The pathologic examination of the surgical specimen showed a multifocal colonic tumor with 3 separate masses. The first mass was located at the transverse colon at the stricture area and showed MiNEN of poorly-differentiated neuroendocrine carcinoma with Ki67 more than 70% and signet cell carcinoma, poorly differentiated, within 1 mm from the serosal surface (Figure 4).

Figure 4.

Figure 4.

Histopathology slides of the mid-transverse colon stricture (A, B) shows the poorly-differentiated neoplasms of the 2 components. (C, D) Cells shows positivity focally for synaptophysin and CD56. (Hematoxylin-eosin and IHC, original magnifications ×4 [A, B, and D] and ×20 [C]).

The other 2 masses were identified at the descending colon, and 1 of the masses had poorly-differentiated signet cell carcinoma (Figure 5), while the other mass was moderately differentiated adenocarcinoma (Figure 6). The pathologic final staging (pTNM, AJCC 8th Edition) was mpT3 N2b M0.

Figure 5.

Figure 5.

(A, B) Histopathology slides of the splenic flexure colon mass showing a poorly-differentiated carcinoma with signet ring cell morphology. (Hematoxylin-eosin, original magnifications ×4 [A] and ×40 [B]).

Figure 6.

Figure 6.

Histopathology slides of the distal descending colon mass shows (A, B) adenocarcinoma with moderate differentiation, and (C) demonstrates vascular invasion. (Hematoxylin-eosin, original magnifications ×4 [A], [B] ×20, and ×40 [C]).

Postoperatively, the patient showed improvement in clinical condition. She was discharged from the ICU and was followed up by Hepatology regarding the liver cirrhosis.

The case was discussed again in the tumor board, and, due to the patient’s comorbidities and performance status, she was considered to be high risk for adjuvant chemotherapy.

Two weeks after discharge, a follow-up examination at the clinic showed that the wounds were completely healed, and after tumor board and family discussion and full explanation of the patient’s advanced condition, the patient and family agreed to continue only with palliative care.

After 6 months, the patient came back to the Emergency Department with severe fatigue and poor oral intake and was found to have severe electrolyte derangements, with severe hyponatremia (sodium level 118) and severe hyperkalemia (potassium level 7.1). After admission, medical and supportive management were started, but the patient died due to respiratory failure.

Discussion

NEN in the colon are rare neoplasms; they account for <1% of colorectal cancers and are extremely rare in the background of IBD. Mixed neuroendocrine non-neuroendocrine neoplasm (MiNEN) is a very rare subtype of tumor that involves a combination of both adenocarcinoma and NEC [3]. NEN associated with UC are twice as common in males as in females, but our patient was a female. It is also known to have poor outcomes, secondary to high metastasis rates (>50% to the liver), and 1-year survival was reported to be 40% [5].

The association between IBD and NEN was reported only in 16 cases in the literature. However, the association between IBD and MiNEN was only reported in 3 cases [620].

Our patient and 3 out of the other reported cases had an interesting pathological diagnosis of MiNEN, which is defined as the presence of >30% of adenocarcinomatous component of the tumor masses [8,11]. Strong staining for synaptophysin and positive Ki67 marker >70% were observed in almost all reported cases, which was similar to our finding [9,20]. Two of the reported cases were found to have rectal MiNEN and 1 was found to have a sigmoid colon MiNEN, while in the presented case a transverse colon MiNEN was found with 2 other masses in the descending colon: poorly-differentiated signet cell carcinoma and moderately differentiated adenocarcinoma [8,11].

Mixed neuroendocrine/non-neuroendocrine neoplasms (MiNENs) are defined as mixed epithelial neoplasms with a neuroendocrine component. Both entities are morphologically and immunohistochemically recognizable as a discrete component with ≥30% of the neoplasm. Most epithelial neoplasms in the GI tract are subdivided into either pure glandular or squamous neoplasms (or their precursors) or pure neuroendocrine neoplasms (NENs). Glandular and squamous neoplasms may exhibit a minor interspersion of neuroendocrine cells that can be identified by immunohistochemistry, but this finding does not affect the classification. Rarely, epithelial neoplasms feature quantitatively significant neuroendocrine and non-neuroendocrine cell populations. Previously, when each component represents ≥30% of the neoplasm, these mixed neoplasms were classified under the category of “mixed adenoneuroendocrine carcinoma” (MANEC). However, because the non-neuroendocrine component may not be adenocarcinoma, and to reflect the possibility that 1 or both components may not be carcinoma, the current term for this category is “mixed neuroendocrine/non-neuroendocrine neoplasm (MiNEN)”.

MiNEN is regarded as a conceptual category of neoplasms rather than a specific diagnosis. Different types of MiNENs arise in different sites throughout the gastroenteropancreatic system [3].

Prognosis and treatment of MiNENs still are unclear, and no well-defined treatment strategy has been established. If resectable intermediate-grade MiNEN is found, surgery should be performed, but if distant metastasis is found, chemotherapy against both types should be started. High-grade MiNEN is the most commonly seen, as in our patient, and is considered the most aggressive type. Localized lesions without distant metastasis are treated with surgery and adjuvant chemotherapy, while systemic chemotherapy is used for distant metastasis [21,22]. According to the latest NCCN guidelines, MiNENs of the GI tract are considered to have poor prognosis and should be managed according to the adenocarcinoma of the colon and rectum guidelines [23].

Conclusions

After encountering this case and reviewing the literature, a clear association was identified and specific characteristics were found between MiNENs and UC. As it is considered rare, this would represent distinct disease features that require further evaluation. Further research studies with larger sample sizes would help to understand the pathogenesis, diagnosis, management, and prognosis.

Footnotes

Department and Institution Where Work Was Done

Department of General Surgery, King Abdulaziz Medical City, Ministry of National Guard-Health Affairs, Riyadh, Saudi Arabia.

Declaration of Figures’ Authenticity

All figures submitted have been created by the authors who confirm that the images are original with no duplication and have not been previously published in whole or in part.

References:

  • 1.Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19(Suppl. A):5A. doi: 10.1155/2005/269076. [DOI] [PubMed] [Google Scholar]
  • 2.Laine L, Kaltenbach T, Barkun A, et al. SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. Gastroenterology. 2015;148:639. doi: 10.1053/j.gastro.2015.01.031. [DOI] [PubMed] [Google Scholar]
  • 3.Nagtegaal ID, Odze RD, Klimstra D, et al. WHO Classification of Tumours Editorial Board. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76(2):182–88. doi: 10.1111/his.13975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Wang J, He A, Feng Q, et al. Gastrointestinal mixed adenoneuroendocrine carcinoma: A population-level analysis of epidemiological trends. J Transl Med. 2020;18(1):128. doi: 10.1186/s12967-020-02293-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Bernick PE, Klimstra DS, Shia J, et al. Neuroendocrine carcinomas of the colon and rectum. Dis Colon Rectum. 2004;47:163–69. doi: 10.1007/s10350-003-0038-1. [DOI] [PubMed] [Google Scholar]
  • 6.Greenstein AJ, Balasubramanian S, Harpaz N, et al. Carcinoid tumor and inflammatory bowel disease: A study of eleven cases and review of the literature. Am J Gastroenterol. 1997;92:682–85. [PubMed] [Google Scholar]
  • 7.Owen DA, Hwang WS, Thorlakson RH, Walli E. Malignant carcinoid tumor complicating chronic ulcerative colitis. Am J Clin Pathol. 1981;76:333–38. doi: 10.1093/ajcp/76.3.333. [DOI] [PubMed] [Google Scholar]
  • 8.Sigel JE, Goldblum JR. Neuroendocrine neoplasms arising in inflammatory bowel disease: A report of 14 cases. Mod Pathol. 1998;11:537–42. [PubMed] [Google Scholar]
  • 9.Freeman HJ, Berean K. Lethal neuroendocrine carcinoma in ulcerative colitis. World J Gastroenterol. 2009;15:5882–83. doi: 10.3748/wjg.15.5882. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Grassia R, Bodini P, Dizioli P, et al. Neuroendocrine carcinomas arising in ulcerative colitis: coincidences or possible correlations? World J Gastroenterol. 2009;15:4193–95. doi: 10.3748/wjg.15.4193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Hayashi H, Miyagi Y, Sekiyama A, et al. Colorectal small cell carcinoma in ulcerative colitis with identical rare p53 gene mutation to associated Adenocarcinoma and dysplasia. J Crohns Colitis. 2012;6:112–15. doi: 10.1016/j.crohns.2011.08.009. [DOI] [PubMed] [Google Scholar]
  • 12.Marchioni Beery RM, Devers TJ, Clement JM. A case of primary colonic small-cell carcinoma arising in a patient with longstanding ulcerative colitis. Gastrointest Cancer Res. 2014;7:119–22. [PMC free article] [PubMed] [Google Scholar]
  • 13.Kosmidis C, Efthimiadis C, Anthimidis G, et al. Small cell carcinoma in ulcerative colitis – new treatment option: a case report. World J Surg Oncol. 2010;8:100. doi: 10.1186/1477-7819-8-100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Yaziji H, Broghamer WL., Jr Primary small cell undifferentiated carcinoma of the rectum associated with ulcerative colitis. South Med J. 1996;89:921–24. doi: 10.1097/00007611-199609000-00016. [DOI] [PubMed] [Google Scholar]
  • 15.Rubin A, Pandya PP. Small cell neuroendocrine carcinoma of the rectum associated with chronic ulcerative colitis. Histopathology. 1990;16:95–97. doi: 10.1111/j.1365-2559.1990.tb01070.x. [DOI] [PubMed] [Google Scholar]
  • 16.Zerboni G, Capurso G, Pilozzi E, Papi C. Colonic small cell neuroendocrine carcinoma in a patient with longstanding ulcerative colitis treated with azathioprine. Dig Liver Dis. 2016;48:822–23. doi: 10.1016/j.dld.2016.03.025. [DOI] [PubMed] [Google Scholar]
  • 17.Sawano M, Esaki M, Maehata Y. Rectal neuroendocrine carcinoma associated with longstanding ulcerative colitis. Dig Endosc. 2016;28:611. doi: 10.1111/den.12640. [DOI] [PubMed] [Google Scholar]
  • 18.Yoshihara T, Shinzaki S, Hiyama S, et al. Metastatic colon neuroendocrine carcinoma found in a patient with ulcerative colitis during annual endoscopic surveillance. Gastrointest Endosc. 2016;84:1075–76. doi: 10.1016/j.gie.2016.01.062. [DOI] [PubMed] [Google Scholar]
  • 19.Lacerda-Filho A, da Mota FF, Lacerda GC, de Castro AF. Small-cell neuroendocrine carcinoma associated with a non-adenoma-like raised lesion in a patient with longstanding ulcerative colitis. J Crohns Colitis. 2016;10:1125–26. doi: 10.1093/ecco-jcc/jjw057. [DOI] [PubMed] [Google Scholar]
  • 20.Bolzacchini E, Chini C, Cortelezzi CC, et al. Poorly differentiated neuroendocrine carcinoma of the sigmoid tract in long-standing ulcerative colitis: Report of a case and review of the literature. Int J Surg Pathol. 2018;26(5):479–83. doi: 10.1177/1066896917752443. [DOI] [PubMed] [Google Scholar]
  • 21.La Rosa S, Marando A, Sessa F, Capella C. Mixed adenoneuroendocrine carcinomas (MANECs) of the gastrointestinal tract: an update. Cancers. 2012;4:11–30. doi: 10.3390/cancers4010011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.La Rosa S, Sessa F, Uccella S. Mixed neuroendocrine-nonneuroendocrine neoplasms (MiNENs): Unifying the concept of a Heterogeneous Group of Neoplasms. Endocr Pathol. 2016;27(4):284–311. doi: 10.1007/s12022-016-9432-9. [DOI] [PubMed] [Google Scholar]
  • 23.Shah MH, Goldner WS, Benson AB, et al. Neuroendocrine and adrenal tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19(7):839–68. doi: 10.6004/jnccn.2021.0032. [DOI] [PubMed] [Google Scholar]

Articles from The American Journal of Case Reports are provided here courtesy of International Scientific Information, Inc.

RESOURCES